TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q)

Summary Among 210 patients with myelodysplastic syndromes (MDSs) with del(5q), molecular information was available at diagnosis or at least 3 months before leukaemic transformation in 146 cases. Multivariate analysis identified therapy‐related setting ( p = 0.02; HR 2.3) and TP53 variant allele frequency (VAF) ≥22% ( p < 0.01; HR 2.8), but not SF3B1 mutation ( p = 0.65), as independent risk factors for survival. Median survival was 11.7 versus 4 years (5/10‐year survival 73%/52% vs. 42%/14%) in the absence ( N = 112) versus presence ( N = 34) of ≥1 risk factors; leukaemia‐free survival was affected by TP53 VAF ≥22% ( p < 0.01). Such information might inform treatment decision‐making in MDS‐del(5q) regarding allogeneic stem cell transplant.